Cabergoline Wikipedia

unagujarat

Cabergoline Wikipedia

In addition to the adverse events that occurred in the patients with hyperprolactinemic disorders, the most common adverse events in patients with Parkinson’s disease were dyskinesia, hallucinations, confusion, and peripheral edema. Heart failure, pleural effusion, pulmonary fibrosis, and gastric or duodenal ulcer occurred rarely. Impulse control/compulsive behaviors, including pathological gambling, increased libido, and hypersexuality, have been reported in patients treated with dopamine agonists including Cabergoline. This has been generally reversible upon reduction of the dose or treatment discontinuation (see Post-marketing Surveillance data). Prescribers should consider dose reduction or stopping the medication if a patient develops such urges while taking Cabergoline.

  • Patients receiving long term treatment with Cabergoline should undergo periodic assessment of their cardiac status and echocardiography should be considered.
  • The pharmacokinetics of Cabergoline were not altered in 12 patients with moderate-to severe renal insufficiency as assessed by creatinine clearance.
  • In urine, the main metabolite identified was 6-allyl-8b-carboxy-ergoline, which accounted for 4-6% of the dose.
  • Cabergoline restores ovulation and fertility in women with hyperprolactinaemic hypogonadism.
  • Heart failure, pleural effusion, pulmonary fibrosis, and gastric or duodenal ulcer occurred rarely.

These losses could be due to the prolactin inhibitory properties of cabergoline in rats. At daily doses of 0.5 mg/kg/day (approximately 19 times the maximum recommended human dose) during the period of organogenesis in the rabbit, cabergoline caused maternotoxicity characterized by a loss of body weight and decreased food consumption. Doses of 4 mg/kg/day (approximately 150 times the maximum recommended human dose) during the period of organogenesis in the rabbit caused an increased occurrence of various malformations. However, in another study in rabbits, no treatment-related malformations or embryofoetotoxicity were observed at doses up to 8 mg/kg/day (approximately 300 times the maximum recommended human dose). A dose of 0.012 mg/kg/day (approximately 1/7 the maximum recommended human dose) during the period of organogenesis in rats caused an increase in post-implantation embryofetal losses.

Cabergoline tablets Dostinex, Cabaser

If you are concerned you should consult your GP or your endocrinologist. This is not a complete list of side effects and others may occur. You may have increased sexual urges, unusual urges to gamble, or other intense urges while taking cabergoline.

Cabergoline – Clinical Pharmacology

Remember that this medication has been prescribed because your doctor has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects. It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies. Ask your pharmacist any questions you have about refilling your prescription.

What about breast feeding?

However, persistent suppression of prolactin levels has been observed for several months in some patients. Of the group of women followed up, 23/29 had ovulatory cycles which continued for greater than 6 months after https://internet-doctor.de/building-muscle-mass-the-ultimate-guide-to/ discontinuation. As with other ergot derivatives, pleuritis, exudative pleura disease, pleura fibrosis, lung fibrosis, and pericarditis are seen. Clinical improvement and normalization of X-ray findings are normally seen soon after cabergoline withdrawal. It appears that the dose typically used for treatment of hyperprolactinemia is too low to cause this type of side effects. Use of Cabergoline for the inhibition or suppression of physiologic lactation is not recommended (see PRECAUTIONS section).